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Abstract
Backgroud A number of agents, including aspirin, non-
steroidal antiinﬂammatory drugs, cyclooxygenase-2 inhibi-
tors, folic acid, calcium, and vitamins, have been evaluated
fortheir potential inchemopreventionof sporadic colorectal
adenomas or cancer. Preclinical data suggest that 5-amino-
salicylates also may have a chemopreventive effect.
Aim To investigate chemoprevention of colonic polyps
with balsalazide, a 5-aminosalicylate prodrug.
Methods In this randomized, double-blind, placebo-
controlled study, adults diagnosed with small polyps in the
rectosigmoid colon were treated with either balsalazide
3 g/d or placebo for 6 months. Follow-up lower endoscopy
was performed, and all polyps were measured and analyzed
histologically. The primary endpoint was reduction in
mean size of the largest polyp per subject.
Results Among 241 participants screened, 86 were ran-
domized to treatment, with 75 subjects evaluable. Balsa-
lazide 3 g/d (n = 38) did not signiﬁcantly reduce the mean
size of the largest colonic polyp or the number of polyps
compared with placebo (n = 37). Although not signiﬁcant,
post-hoc analysis revealed that total adenoma burden per
subject, calculated as the sum of the volumes of all ade-
nomas in mm
3, increased by 55% in the balsalazide group
compared with 95% in the placebo group.
Conclusions Although balsalazide did not have signiﬁ-
cant chemopreventive effects on established colonic pol-
yps, these results can aid in designing future prospective
studies.
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Introduction
Colorectalcanceristhesecondleadingcauseofmalignancy-
related deaths in the United States [1, 2]. In 2007, an esti-
mated 52,000 deaths will result from the disease, and more
than 150,000 new cases will be diagnosed [3]. Most colo-
rectal cancers ([95%) arise from adenomatous polyps
(adenomas) [4, 5]. Adenomas with diameters \1 cm are
common and have a low risk of malignancy, in contrast with
larger adenomas (diameter[1 cm), which have a substan-
tially greater risk of becoming malignant and progressing to
cancer [2, 4–6]. Mortality from colorectal cancer can be
reduced by routine screening of individuals aged 50 years
andolderbycolonoscopy,ﬂexiblesigmoidoscopy,andother
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is the reliable detection of large or advanced adenomas
before they become malignant [5, 7].
Several agents, including nonsteroidal antiinﬂammatory
drugs (NSAIDs; e.g., aspirin, aminosalicylates, cyclooxy-
genase-2 (COX-2) inhibitors), folic acid, calcium, and
vitamins, have been evaluated for their potential in chemo-
preventionofcolorectalcancer[5,8–12].Theadministration
of chemopreventive agents may reduce the incidence of
colorectal cancer, and these agents may act by inhibiting
cell hyperproliferation, enhancing apoptosis, blocking
the accumulation of carcinogenic mutations, or otherwise
slowing the progression from neoplasia to malignancy [9].
5-Aminosalicylates (5-ASAs), ﬁrst-line treatment for
mild-to-moderate ulcerative colitis, have not been evalu-
ated in the chemoprevention of sporadic colorectal cancer
or colonic adenomas. However, patients with inﬂammatory
bowel disease are at increased risk of developing colorectal
cancer [13, 14], and 5-ASAs have been shown in retro-
spective studies to reduce the incidence of dysplasia in
patients with ulcerative colitis [10, 14–20]. However, the
efﬁcacy of 5-ASA in colitis-related colorectal cancer pre-
vention is unclear; some reports demonstrate an association
between early 5-ASA administration and reducing the risk
of developing colorectal cancer [10, 15, 17–20] whereas
others fail to establish such an association [14, 16]. In
addition to its antiinﬂammatory properties, the putative
chemopreventive effect of 5-ASA may be connected to its
ability to induce apoptosis of tumor cells [21] or its ability
to affect cell cycle progression and improve DNA repli-
cation ﬁdelity [22].
The 5-ASA prodrug balsalazide has demonstrated efﬁ-
cacy in the treatment of active [23, 24] and quiescent [25,
26] ulcerative colitis and has been evaluated in established
animal models of colon carcinogenesis [27]. In the Min
mouse model, in which animals are genetically susceptible
to intestinal tumor formation, administration of balsalazide
achieved a reduction of up to 80% in the number of tumors
observed compared with the control group [27]. Addi-
tionally, in rats in which aberrant intestinal crypts were
chemically induced, balsalazide treatment signiﬁcantly
reduced the numbers of aberrant crypt foci by 60% com-
pared with controls [27]. Therefore, investigation of the
efﬁcacy of balsalazide in human colorectal cancer che-
moprevention was warranted. The chemopreventive effects
of 5-ASA could presumably inhibit either the development
of dysplasia, the subsequent growth of dysplastic cells, or
both. This exploratory study is the ﬁrst prospective clinical
study published that tested the second of these two
potential mechanisms by comparing the effect of balsa-
lazide versus placebo in reducing the size and number of
colonic polyps initially identiﬁed during routine screening
by ﬂexible sigmoidoscopy.
Methods
Subjects
Subjects aged 45–80 years, who were scheduled to undergo
lower endoscopy (ﬂexible sigmoidoscopy or colonoscopy)
for colorectal cancer screening and in whom polyps mea-
suring between 3 and 9 mm in diameter were detected in the
rectosigmoid colon, were included in this prospective, ran-
domized, double-blind, placebo-controlled study. Exclusion
criteria included any prior history of colitis, colon cancer,
colonic resection, familial adenomatous polyposis, heredi-
tary nonpolyposis colon cancer (Lynch syndrome), or any
other malignancy; detection of polyps[9 mm in diameter;
administration of anticoagulants, corticosteroids, immuno-
suppressive agents, or NSAIDs during the study; and the
presence of speciﬁc problems that may increase the risk
associated with colonoscopy or mucosal biopsy (i.e, pros-
thetic heart valves, requirement of antibiotic prophylaxis,
platelet count \50,000/mm
3, myocardial infarction in the
past three months, coagulopathy, severe congestive heart
failure, chronic obstructive pulmonary disease, or unstable
coronary artery disease). Initially aspirin was excluded as a
concomitant medication. However, the high percentage of
subjects at the study site receiving low-dose aspirin made
recruitmentdifﬁcult.Therefore,theprotocolwasamendedto
allow concomitant aspirin use (B325 mg/d), and randomi-
zation was stratiﬁed by concomitant aspirin use. The study
was performed at the San Francisco Veterans Affairs Med-
ical Center. The study was approved by the institutional
review board and all subjects provided written informed
consent.
Screening and Treatment
At the initial screening visit, subjects underwent regularly
scheduled endoscopy, and polyps between 3 and 9 mm in
diameter in the rectosigmoid colon (within 50 cm of the
anal verge) were photographed, measured using the open
biopsy forceps method, and their distance from the anal
verge recorded. Mucosa adjacent to the polyps was tattooed
with India ink to facilitate re-identiﬁcation at follow-up
endoscopy. Polyps were not biopsied during the initial
endoscopy, so histological assessment of the polyps at study
enrollment was not possible. Biopsies of normal rectal
mucosa were taken for analysis of apoptosis. Participants
were randomized to receive either balsalazide (Colazal;
Salix Pharmaceuticals, Morrisville, NC, USA) 3 g/d (two
750-mg capsules twice daily) or placebo for 6 months.
Participants returned for follow-up visits after 1, 3, and
5 months to determine treatment compliance based on pill
counts, administration of any concomitant medications, and
the occurrence of any adverse events. Following 6 months
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endoscopy (complete colonoscopy if initial exam was a
ﬂexible sigmoidoscopy and vice versa). All previously tat-
tooed rectosigmoid polyps, and any new rectosigmoid
polyps, were measured and then completely removed and
sent for histological analysis. Polyps observed proximal to
the rectosigmoid colon (i.e.,[50 cm from the anal verge)
were removed but were not part of the analysis. Biopsies of
normal-appearing rectal mucosa again were taken. The
same endoscopist performed the initial and follow-up
endoscopies.
Assessments
The primary study efﬁcacy endpoint was reduction in mean
size of the largest rectosigmoid polyp per subject at
6 months. Secondary endpoints included reduction in total
number of polyps, reduction in mean size of adenomatous
polyps, reduction in the proportion of subjects with an
increase in adenomatous polyp size, reduction in total
adenoma burden, and change in apoptotic index of rectal
mucosa. Adenoma burden was assessed at baseline and
follow-up by summing the calculated volumes of all of the
adenomas using the measured diameters of the polyps and
assuming the polyps to be spherical.
Eight rectal mucosal pinch biopsies from normal tissue
were obtained before randomization and after 6 months of
treatment. Apoptotic cells were detected by the terminal
deoxynucleotidyl transferase-mediated dUTP nick end
labeling (TUNEL) method [28] using terminal transferase
to enzymatically incorporate digoxigenin-labeled nucleo-
tides into the 30-terminus of the fragmented DNA charac-
teristic of apoptotic cells, followed by the detection of
incorporated label using standard immunohistochemical
techniques. Apoptotic indices were then determined by
scoring 1,000 rectal epithelial cells for TUNEL positivity.
Statistical Analysis
A total sample size of 200 subjects was planned in order to
provide 80% power to detect a 20% change in the mean
size of the largest polyp per subject between the two
treatment groups. Because of difﬁculty in recruitment, even
with expanding eligibility to include subjects taking aspi-
rin, the total planned accrual was not achieved. After 86
subjects had been randomized, a decision was made to stop
further enrollment and to perform an interim data analysis.
Based on this analysis, it became clear that it would not be
possible to reject the null hypothesis and detect a 20%
change in mean polyp size with the planned 80% power
even if the initial enrollment target was met, so a decision
was made to terminate the study. Comparability of the two
treatment groups at randomization was analyzed using the
chi-square statistic for categorical variables and a t statistic
for continuous variables. Similar analyses using a t statistic
were carried out to determine a difference in mean change
in polyp size due to treatment. Changes between the two
study arms in apoptotic indices of rectal mucosa were also
analyzed with the same methods.
Results
Subject Population
Among the 241 subjects screened after providing informed
consent, 86 subjects with rectosigmoid polyps between 3
and 9 mm were randomized to receive balsalazide 3 g/d
(n = 44) or placebo (n = 42; Fig. 1). Of the 86 random-
ized subjects, 75 completed the study (38 in the balsalazide
group and 37 in the placebo group) and had polyps that
could be compared at baseline and at the end of treatment,
and were therefore included in the evaluable population
(Table 1). The non-evaluable study subjects all withdrew
consent to participate in the study after randomization and
therefore did not take study medication. The subjects were
all male, and mean age was comparable between groups.
All of the evaluable subjects took [80% of their study
medications, and there was no difference in adherence
between groups. The India ink tattoos were identiﬁed in all
study subjects except one who had been treated with
placebo and in whom the baseline polyp was not visible at
follow-up exam. The mean number of polyps per subject
and the mean size of the largest polyp per subject did not
differ signiﬁcantly at baseline between treatment groups.
There was, however, a signiﬁcant difference (P = 0.03) in
distribution of polyp histologic type between groups. Pol-
yps detected at baseline in the subjects randomized to
balsalazide treatment were more frequently identiﬁed as
adenomas upon histologic examination (26 of 56 polyps;
46%) compared with placebo-treated subjects (13 of 53
polyps; 25%). In addition, the proportion of subjects with
at least one adenoma at baseline was higher for the
balsalazide group than for the placebo group (68 vs. 43%,
respectively; P = 0.04).
Primary Analysis: Change in Mean Size of Largest
Polyp Per Subject
After 6 months of treatment, marked polyps were re-
measured and removed for histologic analysis. For the
primary study endpoint, there was no signiﬁcant difference
between groups in the mean change in diameter of the
largest polyp per subject after 6 months of treatment
(Table 2). For balsalazide-treated subjects, the mean
2490 Dig Dis Sci (2009) 54:2488–2496
123Enrollment
N=241
Patients without polyps 
n=155
Randomized to balsalazide 3 g/d 
n=44
Randomized to placebo 
n=42
Placebo patients completed 
n=37
Reasons for discontinuation:  
Lost to follow-up   n=5 
Balsalazide patients completed 
n=38
Reasons for discontinuation: 
Lost to follow-up   n=6 
Fig. 1 Flow of patients through the study. Patients in whom polyps were detected by colonoscopy were randomized for inclusion in the study
Table 1 Subject demographics
and baseline polyp
characteristics for evaluable
population
SD standard deviation, NS not
signiﬁcant
Balsalazide
3 g/d (n = 38)
Placebo
(n = 37)
P value
Mean age (y ± SD) 63 ± 12 63 ± 13 NS
Reporting concomitant aspirin use, n (%) 17 (45) 15 (41) NS
Mean number of polyps/subject (n ± SD)
All evaluable subjects 1.9 ± 1.5 1.9 ± 1.1 NS
Receiving concomitant aspirin 2.0 ± 1.0 1.3 ± 0.6 0.02
No concomitant aspirin 1.8 ± 1.8 2.3 ± 1.1 NS
Range of number of polyps/subject 1–9 1–4
Subjects with[1 polyp, n (%)
All evaluable subjects 17 (45) 18 (49) NS
Receiving concomitant aspirin 10 (59) 3 (21) 0.04
No concomitant aspirin 7 (21) 15 (68) 0.03
Mean size of largest polyp/subject (mm ± SD)
All evaluable subjects 5.5 ± 1.7 5.4 ± 1.9 NS
Receiving concomitant aspirin 6.1 ± 2.0 5.0 ± 1.9 NS
No concomitant aspirin 5.0 ± 1.4 5.7 ± 1.8 NS
At 6-month follow-up
Polyp histology, number of subjects
Hyperplastic 8 19
Adenomatous 14 7 0.03
Both 12 9
Subjects with C1 adenoma at follow-up, n/N (%)
All evaluable subjects 26/38 (68) 16/37 (43) 0.04
Receiving concomitant aspirin 13/17 (76) 5/15 (33) 0.03
No concomitant aspirin 13/21 (62) 11/22 (50) NS
Subjects with no initial adenomas but
C1 adenoma at follow-up, n/N (%)
4/38 (11) 3/37 (8) NS
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123change in the size of the largest polyp was 0.2 ± 1.5 mm.
For placebo-treated subjects, the mean change in the size of
the largest polyp was -0.5 ± 2.2 mm. Similar results were
observed regardless of whether subjects were receiving
concomitant aspirin therapy.
Change in Polyp Number
There was no signiﬁcant difference in the change in total
polyp number at follow-up between treatment groups. The
missed or new polyp rate (i.e., histologically identiﬁed
polyps at follow-up but not marked at baseline) was similar
between the two groups. In the balsalazide group, 17 sub-
jects presented at the 6-month follow-up visit with polyps
not identiﬁed at baseline; similarly, in the placebo group, 18
subjects presented at follow-up with polyps not identiﬁed at
baseline (Table 3). When these newly identiﬁed polyps
were added to the originally identiﬁed and marked polyps,
the missed and/or new polyp proportion was calculated to
be 30.8% in the balsalazide group and 30.2% in the placebo
group. Similarly, there was no difference in the number of
polyps which were detected at baseline, but then not
detected at the follow-up exam, between groups (three
polyps in the balsalazide group and four in the placebo
group, Fisher’s exact test: P = 1.0).
Secondary Analysis: Change in Adenoma Size
All adenomatous polyps removed were tubular adenomas.
Overall, there was no difference in the mean change in size
of the largest adenomatous polyps when comparing
balsalazide-treated subjects with those receiving placebo
(Table 2). Among subjects who received aspirin concom-
itantly, adenomas identiﬁed in subjects treated with
balsalazide showed a smaller size increase per subject
compared with adenomas identiﬁed in subjects treated with
placebo, but this difference was not signiﬁcant (Table 2).
Among subjects who presented at follow-up with new
adenomas, the mean size of all newly identiﬁed adenomas
did not differ between treatment groups (Table 3). Among
Table 2 Effect of 6 months of treatment on polyp growth
Assessment Balsalazide 3 g/d Placebo P value
n mm ± SD n mm ± SD
Largest polyp: change in mean size after 6 months
All evaluable subjects 38 0.2 ± 1.5 37 -0.5 ± 2.2 NS
Receiving concomitant aspirin 17 0.06 ± 1.2 15 -0.53 ± 2.5 NS
No concomitant aspirin 21 0.30 ± 1.7 22 -0.45 ± 2.0 NS
Largest adenoma: change in mean size after 6 months
All evaluable subjects 22 0.3 ± 1.6 13 0.5 ± 1.7 NS
Receiving concomitant aspirin 13 -0.1 ± 1.2 5 0.8 ± 1.6 NS
No concomitant aspirin 9 0.8 ± 2.0 8 0.3 ± 1.8 NS
SD standard deviation, NS not signiﬁcant
Table 3 New or missing
polyps detected after 6 months
of treatment
SD standard deviation
Assessment Balsalazide
3 g/d (n = 38)
Placebo
(n = 37)
Subjects with new polyps with histology at 6 months (n)1 7 1 8
Hyperplastic only 4 4
Tubular adenoma only 8 12
Both 5 2
Mean size of new polyps (mm ± SD)
Hyperplastic 3.2 ± 1.5 3.7 ± 1.6
Tubular adenoma 5.2 ± 1.7 6.2 ± 5.1
Mean size of new adenomas (mm)
Receiving concomitant aspirin 5.3 (n = 3) 5.0 (n = 1)
No concomitant aspirin 5.1 (n = 6) 6.4 (n = 5)
Polyps not detected at 6-month follow-up visit
Subjects, n (aspirin; no aspirin) 3 (2; 1) 4 (2; 2)
Mean size at baseline (mm) 3.4 (n = 5) 5.2 (n = 5)
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123subjects not taking concomitant aspirin, new adenomas
were smaller among those given balsalazide compared with
placebo, but this difference did not reach signiﬁcance.
Secondary Analysis: Apoptotic Markers
To determine if balsalazide treatment would affect the rate
of apoptosis, the change from baseline in the apoptotic
index in rectal mucosa was assessed after 6 months of
treatment. Increased TUNEL was detected in 70% of
balsalazide-treated subjects compared with 58% of pla-
cebo-treated subjects (Fig. 2). In addition, a nonsigniﬁcant
trend in favor of balsalazide was observed in the magnitude
of the mean change in apoptotic index (balsalazide,
0.99 ± 2.58; placebo, 0.38 ± 1.04).
Exploratory Analysis: Total Adenoma Burden
Among subjects who received balsalazide, the mean ade-
noma burden per subject at baseline was 157.0 versus
128.9 mm
3 for subjects receiving placebo. Following
treatment, these increased to 189.3 and 184.6 mm
3,
respectively. This resulted in a mean increased adenoma
burden of 55% for those treated with balsalazide compared
with a mean increased adenoma burden of 95% for the
placebo-treated subjects. This difference was because of a
greater, although non-signiﬁcant, increase in the mean
burden in placebo-treated subjects compared with balsa-
lazide-treated subjects (Table 4).
Safety
Balsalazide was well tolerated in this study, and no sig-
niﬁcant differences in incidence of adverse events were
reported between the two treatment groups.
Discussion
Agents that can prevent the growth of polyps, reduce their
size, or cause their complete regression are likely to help
reduce the risk for development of colorectal cancer [4].
Thus, a reduction in adenoma size or number serves as a
surrogate marker for chemoprevention of colorectal cancer
[11]. Because salicylates such as aspirin have shown
positive correlations with reduced colorectal cancer inci-
dence [8], the well-tolerated 5-aminosalicylate prodrug
balsalazide was prospectively evaluated for its ability to
reduce the size and/or number of established, diminutive
polyps over a 6-month treatment period. 5-Aminosalicy-
lates may well prevent the development of dysplasia in
patients with longstanding ulcerative colitis [29], but their
ability to prevent sporadic colorectal neoplasia in humans
has not been studied.
Although the rationale for this randomized, double-
blind, placebo-controlled, exploratory study was sound, the
major endpoints of the study were not achieved. No sig-
niﬁcant difference in the mean change in size of the largest
polyp, nor in the total number of polyps, was detected
between subjects who received balsalazide or placebo over
6 months.
It should be noted, however, that the primary endpoint
of this study considered all identiﬁed polyps regardless of
histologic type. However, even when the analyses were
conﬁned to only tubular adenomas, no clear difference in
the mean change of size or number of adenomas was seen
between treatment groups. Thus, the results do not support
the hypothesis that balsalazide treatment for 6 months is
able to reduce the size of existing, diminutive colorectal
polyps as deﬁned in this prospective analysis plan.
It should be considered whether this result is because the
study sample size was insufﬁcient for detection of the
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Fig. 2 Change from baseline in TUNEL apoptotic index after
6 months of treatment with balsalazide 3 g/d (n = 38) or placebo
(n = 37). Bars represent the change from baseline for each subject.
TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick
end labeling
Table 4 Adenoma burden before and after 6 months of treatment
Assessment Balsalazide
3 g/d
(n = 22)
Placebo
(n = 13)
Burden per subject at baseline
(mm
3 ± SD)
157.0 ± 110.9 128.8 ± 89.3
Burden per subject at 6 months
(mm
3 ± SD)
189.3 ± 130.4 184.6 ± 145.8
Change of mean burden
(mm
3 ± SD)
32.3 ± 130.5 55.7 ± 102.5
Mean of per subject change (%) ?55.7% ?95.0%
Burden increase (N, mean % change) 9 (?166%) 6 (?222%)
Burden no change (N, % change) 8 (0) 5 (0)
Burden decrease (N, % change) 5 (-56.5%) 2 (-47.2%)
Includes only subjects with both baseline and 6-month measurements
SD standard deviation
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123proposed difference for the speciﬁed type II error, or
whether or not an inability to measure polyp size with
sufﬁcient accuracy would preclude our ability to assess the
primary endpoint. A total population of 200 had been
planned in order to detect a 20% change in the mean size of
the largest polyp per subject with balsalazide compared
with placebo. Given that the mean size of the baseline
polyps was 5–6 mm, a 20% change in size would be
approximately 1–1.2 mm. In terms of measurement accu-
racy, we used a standard methodology and we feel conﬁ-
dent that we are able to accurately detect changes in size of
1 mm or more in polyp size. However, no gold standard
exists for polyp measurement in situ, and we have no way
of unequivocally demonstrating the accuracy and precision
of our measurements. In terms of sample size, the target
was not achieved, because of slow enrollment. However,
after analyzing the data from 75 evaluable subjects, the
mean size of the largest polyp in the placebo group
decreased by 7.2% whereas the mean size of the largest
polyp in the balsalazide-treated subjects increased by 4.5%.
Therefore, it is very unlikely that the primary endpoint of
the study would have been achieved even if the target
enrollment had been met. In addition, no difference
between groups was noted for the easier to assess endpoint
of change in polyp number. We conclude, therefore, that
the neither the small sample size, nor the accuracy of our
polyp measurements, affected our ﬁnding that balsalazide
does not cause a clinically important retardation or
regression of growth in diminutive polyps.
Adenoma growth, not polyp growth, is the better end-
point to assess the colorectal cancer chemopreventive
effect of a drug. The analysis of changes in adenoma size
over time is complicated by the fact that a marked polyp
can:
1 increase in size;
2 not change in size; or
3 decrease in size.
Unfortunately, an analysis that is focused only on the
mean change in size per subject in the entire group fails to
account for the possibility that these three types of out-
comes can counteract each other in the analysis and greatly
increase the standard deviation, possibly resulting in a
smaller observed effect size.
To attempt to overcome this limitation, an exploratory
analysis examined the overall adenoma burden per subject.
This takes into account all potential neoplastic tissue
identiﬁed and is not limited to the largest adenoma only.
This analysis showed that subjects given placebo had a
greater, though non-signiﬁcant, increase in adenoma bur-
den than those treated with balsalazide. This observation
suggests, though in no way conﬁrms, that balsalazide may
retard adenoma growth.
The study design also limited the ability to determine if
balsalazide has a chemopreventive effect regarding spo-
radic colorectal neoplasia. The analysis was limited to
subjects with small polyps in the distal colon, the treatment
duration was only 6 months, and the dose of balsalazide
was set at 3 g per day. The reason for limiting the analysis
to subjects with small polyps in the distal colon was
because most of the subjects underwent a ﬂexible sig-
moidoscopy as their initial exam. Therefore no baseline
assessment was undertaken of the proximal colon. In
addition, it was felt to be unsafe to leave polyps greater
than 9 mm in situ for 6 months, or to allow subjects with
distal polyps of this size to wait 6 months to have an
endoscopic evaluation of their proximal colons. The dose
of balsalazide employed in the study was based on pre-
clinical data, dosing convenience, and dose–response data
for the maintenance of remission in ulcerative colitis [25–
27]. We acknowledge that the ability of balsalazide to
prevent the occurrence or recurrence of colorectal neo-
plasia was not studied, nor was the effect of balsalazide on
larger or more advanced or more proximal neoplasias, nor
was the effect of higher doses of balsalazide. The study
design employed was chosen to maximize safety and to
minimize study duration and cost and has been successful
in demonstrating the chemopreventive actions of NSAIDs
and COX-2 inhibitors in patients with familial adenoma-
tous polyposis [30, 31].
The potential chemopreventive action of balsalazide or
other 5-ASAs in colorectal neoplasia has been suggested by
preclinical studies [27], although the potential chemopre-
ventive mechanism remains unclear. Although only a small,
nonsigniﬁcant increase in TUNEL of rectal biopsies was
observed in the balsalazide group compared with the pla-
cebo group in this study, this positive trend was consistent
with reports of the proapoptotic effect of 5-ASAs on colonic
epithelial cells in vitro [27]. Several studies suggest a mul-
tiplicity of actions that may contribute to the possible che-
mopreventive actions of 5-ASA (reviewed by Rubin et al.
[29]). These include functioning as a peroxisome prolifer-
ator-activated receptor c agonist and as a factor involved in
the maintenance of intestinal mucosal integrity [32], DNA
replicationﬁdelity [33],and cell cycle accumulationin the S
phase [22]. These actions contribute to a more controlled,
less proliferative population of epithelial cells in the colonic
mucosa, and contribute to the induction of apoptosis in
dysplastic cells. It is very unlikely that COX-2 inhibition is
the primary mechanism of 5-ASA action. 5-Aminosalicy-
lates are weak direct inhibitors of COX-2, unlike ASA and
NSAIDs; however, they are potent inhibitors of the tran-
scription factor nuclear factor-kappa B (NF-jB). Recent
preclinical data suggest that NF-jB may play an impor-
tant role in the development of colorectal neoplasia, possi-
bly through upstream induction of COX-2, increased
2494 Dig Dis Sci (2009) 54:2488–2496
123prostaglandin E2 production, and activation of epidermal
growth factor receptor signaling [34].
In conclusion, this study failed to show that balsalazide
3 g/d for 6 months could reduce the size or number of
diminutive colonic polyps. Nor was there evidence of
balsalazide reducing the size or number of colonic adeno-
mas. However, the greater increase in adenoma burden
among subjects receiving placebo compared with balsa-
lazide, in conjunction with mechanistic and preclinical
data, still suggest that 5-ASA agents such as balsalazide
might be effective in preventing or slowing the growth of
colorectal neoplasia. To fully explore the ability of balsa-
lazide to prevent or slow the progression of colonic ade-
nomas or colorectal cancer, larger and longer prospective
studies with a different study design will need to be
undertaken.
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